Systemic and Tissue Inflammation in Juvenile Dermatomyositis: From Pathogenesis to the Quest for Monitoring Tools
- PMID: 30619311
- PMCID: PMC6305419
- DOI: 10.3389/fimmu.2018.02951
Systemic and Tissue Inflammation in Juvenile Dermatomyositis: From Pathogenesis to the Quest for Monitoring Tools
Abstract
Juvenile Dermatomyositis (JDM) is a systemic immune-mediated disease of childhood, characterized by muscle weakness, and a typical skin rash. Other organ systems and tissues such as the lungs, heart, and intestines can be involved, but may be under-evaluated. The inflammatory process in JDM is characterized by an interferon signature and infiltration of immune cells such as T cells and plasmacytoid dendritic cells into the affected tissues. Vasculopathy due to loss and dysfunction of endothelial cells as a result of the inflammation is thought to underlie the symptoms in most organs and tissues. JDM is a heterogeneous disease, and several disease phenotypes, each with a varying combination of affected tissues and organs, are linked to the presence of myositis autoantibodies. These autoantibodies have therefore been extensively studied as biomarkers for the disease phenotype and its associated prognosis. Next to identifying the JDM phenotype, monitoring of disease activity and disease-inflicted damage not only in muscle and skin, but also in other organs and tissues, is an important part of clinical follow-up, as these are key determinants for the long-term outcomes of patients. Various monitoring tools are currently available, among which clinical assessment, histopathological investigation of muscle and skin biopsies, and laboratory testing of blood for specific biomarkers. These investigations also give novel insights into the underlying immunological processes that drive inflammation in JDM and suggest a strong link between the interferon signature and vasculopathy. New tools are being developed in the quest for minimally invasive, but sensitive and specific diagnostic methods that correlate well with clinical symptoms or reflect local, low-grade inflammation. In this review we will discuss the types of (extra)muscular tissue inflammation in JDM and their relation to vasculopathic changes, critically assess the available diagnostic methods including myositis autoantibodies and newly identified biomarkers, and reflect on the immunopathogenic implications of identified markers.
Keywords: autoantibodies; biomarkers; disease monitoring; interferon signature; juvenile dermatomyositis; personalized medicine; tissue inflammation; vasculopathy.
Figures

Similar articles
-
Expression of interferon-regulated genes in juvenile dermatomyositis versus Mendelian autoinflammatory interferonopathies.Arthritis Res Ther. 2020 Apr 6;22(1):69. doi: 10.1186/s13075-020-02160-9. Arthritis Res Ther. 2020. PMID: 32252809 Free PMC article.
-
Juvenile dermatomyositis: advances in clinical presentation, myositis-specific antibodies and treatment.World J Pediatr. 2020 Feb;16(1):31-43. doi: 10.1007/s12519-019-00313-8. Epub 2019 Sep 26. World J Pediatr. 2020. PMID: 31556011 Review.
-
Pulmonary function and autoantibodies in a long-term follow-up of juvenile dermatomyositis patients.Rheumatology (Oxford). 2014 Apr;53(4):644-9. doi: 10.1093/rheumatology/ket380. Epub 2013 Dec 5. Rheumatology (Oxford). 2014. PMID: 24310298
-
Expression of myxovirus-resistance protein A: a possible marker of muscle disease activity and autoantibody specificities in juvenile dermatomyositis.Neuropathol Appl Neurobiol. 2019 Jun;45(4):410-420. doi: 10.1111/nan.12498. Epub 2018 Jun 4. Neuropathol Appl Neurobiol. 2019. PMID: 29770465 Free PMC article.
-
Updates on Juvenile Dermatomyositis from the Last Decade: Classification to Outcomes.Rheum Dis Clin North Am. 2021 Nov;47(4):669-690. doi: 10.1016/j.rdc.2021.07.003. Epub 2021 Sep 2. Rheum Dis Clin North Am. 2021. PMID: 34635298 Free PMC article. Review.
Cited by
-
Metabolomics analysis identifies a lipidomic profile in treatment-naïve juvenile dermatomyositis patients vs healthy control subjects.Rheumatology (Oxford). 2022 Apr 11;61(4):1699-1708. doi: 10.1093/rheumatology/keab520. Rheumatology (Oxford). 2022. PMID: 34185053 Free PMC article.
-
Inflammasomes and Childhood Autoimmune Diseases: A Review of Current Knowledge.Clin Rev Allergy Immunol. 2021 Oct;61(2):156-170. doi: 10.1007/s12016-020-08825-2. Epub 2020 Nov 25. Clin Rev Allergy Immunol. 2021. PMID: 33236284 Free PMC article. Review.
-
[Advances on the research and treatment of autoimmune disease-related chronic wounds].Zhonghua Shao Shang Yu Chuang Mian Xiu Fu Za Zhi. 2022 Jun 20;38(6):563-568. doi: 10.3760/cma.j.cn501225-20220329-00101. Zhonghua Shao Shang Yu Chuang Mian Xiu Fu Za Zhi. 2022. PMID: 35764583 Free PMC article. Review. Chinese.
-
Monogenic Autoinflammatory Diseases: State of the Art and Future Perspectives.Int J Mol Sci. 2021 Jun 14;22(12):6360. doi: 10.3390/ijms22126360. Int J Mol Sci. 2021. PMID: 34198614 Free PMC article. Review.
-
T cell interaction with activated endothelial cells primes for tissue-residency.Front Immunol. 2022 Sep 12;13:827786. doi: 10.3389/fimmu.2022.827786. eCollection 2022. Front Immunol. 2022. PMID: 36172363 Free PMC article.
References
-
- Rothwell S, Cooper RG, Lundberg IE, Miller FW, Gregersen PK, Bowes J, et al. . Dense genotyping of immune-related loci in idiopathic inflammatory myopathies confirms HLA alleles as the strongest genetic risk factor and suggests different genetic background for major clinical subgroups. Ann Rheum Dis. (2016) 75:1558–66. 10.1136/annrheumdis-2015-208119 - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical